MSK Research Drives 11 FDA Cancer Drug Approvals in 2025
Memorial Sloan Kettering-led trials produced 11 new FDA-approved cancer therapies in a single year, spanning multiple tumor types.
Summary
Memorial Sloan Kettering Cancer Center (MSK) announced that research it led contributed to 11 new FDA drug approvals for cancer in 2025 — a remarkable output from a single institution in one calendar year. The approvals span multiple cancer types and therapeutic modalities, reflecting MSK's broad clinical trial portfolio. Among the notable approvals is pembrolizumab (Keytruda) in combination with paclitaxel for PD-L1–expressing, platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma in patients who have received one or two prior treatment regimens. This wave of approvals underscores the accelerating pace of oncology drug development and the critical role academic cancer centers play in translating basic science into approved therapies. For clinicians, it signals expanding treatment options across several hard-to-treat cancer categories. For patients, these approvals represent new hope, particularly in cancers with historically limited second-line options.
Detailed Summary
Memorial Sloan Kettering Cancer Center (MSK) reported that its researchers played a lead role in securing 11 new FDA drug approvals for cancer treatments during 2025. This announcement highlights the outsized contribution academic cancer centers make to the oncology pipeline — from early-phase trials through pivotal studies that support regulatory submissions.
Among the confirmed approvals tied to MSK-led research is pembrolizumab (Keytruda) combined with paclitaxel, with or without bevacizumab, for adult patients with PD-L1–expressing platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who have received one or two prior systemic regimens. This expands immunotherapy options into a disease setting where durable responses have historically been elusive.
The broader set of 11 approvals spans diverse tumor types and mechanisms of action. While the full list was not available in the source abstract, the scope suggests progress across solid tumors and hematologic malignancies, including novel combinations, biomarker-selected populations, and potentially new drug classes entering clinical use.
For oncologists and clinicians, the practical implication is significant: treatment algorithms across multiple cancer types will need updating, and biomarker testing — particularly PD-L1 and other predictive markers — becomes increasingly important for patient selection. For health-conscious patients and longevity-focused audiences, these approvals signal that precision oncology is advancing rapidly, with more targeted and potentially less toxic options becoming available.
Caveats apply: the original press release content could not be fully verified from primary FDA sources at the time of this summary, and the detailed list of all 11 drugs, their indications, and supporting trial data requires confirmation from official FDA approval announcements and published trial results. This summary is based on the abstract and secondary reporting only.
Key Findings
- MSK-led research contributed to 11 new FDA cancer drug approvals in 2025, an exceptional annual output.
- Pembrolizumab plus paclitaxel approved for PD-L1–positive platinum-resistant ovarian cancer patients.
- Approvals span multiple tumor types, expanding precision oncology options across hard-to-treat cancers.
- Biomarker-driven patient selection, especially PD-L1 testing, is central to multiple new approvals.
- Academic cancer centers are accelerating the translation of clinical research into approved therapies.
Methodology
This is a press release summary from MSK describing FDA approvals linked to its clinical research portfolio in 2025. The underlying evidence base for each approval derives from randomized controlled trials and pivotal clinical studies submitted to the FDA. Specific trial designs vary by drug and indication.
Study Limitations
This summary is based on the abstract and a secondary press release only — the full list of all 11 approved drugs, their specific indications, and supporting trial data could not be independently verified from primary FDA sources at time of publication. The published date listed (2026-05-19) may reflect a reporting or metadata discrepancy. Readers should consult FDA.gov and official prescribing information for authoritative details.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.